Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Department of Surgery, Tokyo Medical University, Tokyo, Japan.
Eur J Cardiothorac Surg. 2022 Aug 3;62(3). doi: 10.1093/ejcts/ezac166.
The aim of this study was to assess the clinical effects of a small ground-glass opacity (GGO) component of a radiologically nearly pure-solid tumour on tumour aggressiveness in patients with clinical stage IA non-small-cell lung cancer (NSCLC).
Data of 988 patients with clinical stage IA NSCLC who had a consolidation-to-tumour ratio of ≥0.75 on high-resolution computed tomography were retrospectively analysed. The cumulative incidence of recurrence (CIR) was compared between patients with GGO (nearly pure-solid, n = 297) and those without GGO (pure-solid, n = 691).
In patients with clinical T1mi + T1a and T1b, the CIR was significantly higher in the pure-solid group than in the nearly pure-solid group (5-year CIR, 15.2% and 19.3% vs 0% and 6.4%; P < 0.001); however, this was not the case for patients with clinical T1c (5-year CIR, 23.1% vs 26.5%; P = 0.580). In the multivariable analysis, pure-solid tumours were independently associated with a higher CIR than nearly pure-solid tumours in patients with clinical T1mi + T1a + T1b (solid tumour size ≤2 cm; subdistribution hazard ratio, 3.25; 95% confidence interval, 1.59-6.63; P = 0.001) but not in those with clinical T1c tumours (2-3 cm; subdistribution hazard ratio, 0.67; 95% confidence interval, 0.39-1.13; P = 0.130).
Nearly pure-solid tumours with a small GGO component influence tumour aggressiveness based on solid tumour size, with a threshold of 2 cm in patients with clinical stage IA NSCLC. For tumours sized 2-3 cm, nearly pure-solid tumours had a similar tumour aggressiveness as pure-solid tumours.
本研究旨在评估影像学上接近纯实性肿瘤中存在小磨玻璃密度(GGO)成分对临床 IA 期非小细胞肺癌(NSCLC)患者肿瘤侵袭性的影响。
回顾性分析了 988 例临床 IA 期 NSCLC 患者的高分辨率 CT 上实性成分与肿瘤比值≥0.75 的数据。比较了 GGO(近纯实性,n=297 例)与无 GGO(纯实性,n=691 例)患者的复发累积发生率(CIR)。
在临床 T1mi+T1a 和 T1b 患者中,纯实性组的 CIR 明显高于近纯实性组(5 年 CIR,分别为 15.2%和 19.3%与 0%和 6.4%;P<0.001);然而,临床 T1c 患者并非如此(5 年 CIR,分别为 23.1%和 26.5%;P=0.580)。多变量分析显示,在临床 T1mi+T1a+T1b 患者中,与近纯实性肿瘤相比,纯实性肿瘤与更高的 CIR 独立相关(肿瘤大小≤2cm;亚分布危险比,3.25;95%置信区间,1.59-6.63;P=0.001),但在临床 T1c 肿瘤患者中并非如此(2-3cm;亚分布危险比,0.67;95%置信区间,0.39-1.13;P=0.130)。
基于实体瘤大小,临床 IA 期 NSCLC 中存在小 GGO 成分的近纯实性肿瘤会影响肿瘤侵袭性,阈值为 2cm。对于 2-3cm 大小的肿瘤,近纯实性肿瘤与纯实性肿瘤具有相似的肿瘤侵袭性。